Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : The thread of life -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (637)	12/20/2004 8:47:56 PM
From: Mike McFarland	Respond to of 1336

The history of Horizon bizjournals.com bizjournals.com cooley.com Tartaglia--I'll have to root around and read up about this fellow. And the MC-4 antagonists program too. I thought it was Tenthoff who said this all would result, paraphrasing here, in a much higher burn rate. But I cannot find the quote, so it may be another analyst.

To: Mike McFarland who wrote (637)	1/30/2005 1:27:12 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 1336

Horizon horizons bio-itworld.com June 12th, 2002! Very pertinent today! Q: What types of studies do you expect to see in the future? A: We anticipate that companies will use pharmacogenomics to rescue drugs that might otherwise fail because of an outlier (a large effect seen in a small number of patients). If the drug is working well, but one or a few patients show high blood levels, the company may be able to go back, do either a whole genome scan of those individuals or a candidate gene polymorphism study, and provide a genetic explanation that would satisfy a reviewer. You could also rescue drugs that have been withdrawn. Let's say a drug gets approved, but it experiences adverse events in the marketplace. If pharmacogenetics is used as a surveillance tool, it can then also be used in a prospective way to better target the drug. Also, you may be able to apply pharmacogenetic information to the next drug that the company is developing in that same drug class. -------------------------- Up only $300 in poker now, and down 12% in my stock $57k -$7k -12% $50,687